Disseminated Tumor Cells in Bone Marrow Following Definitive Radiotherapy for Intermediate or High-Risk Prostate Cancer

被引:4
作者
Berg, Arne [1 ]
Bruland, Oyvind S. [1 ,2 ]
Fossa, Sophie D. [1 ,2 ]
Nesland, Jahn M. [1 ,3 ]
Berner, Aasmund [3 ]
Schirmer, Cecilie [3 ]
Lilleby, Wolfgang [2 ]
机构
[1] Univ Oslo, Fac Div Norwegian Radium Hosp, Fac Med, N-0310 Oslo, Norway
[2] Univ Hosp, Rikshosp, Div Canc Med & Radiotherapy, Oslo, Norway
[3] Univ Hosp, Rikshosp, Div Pathol, Oslo, Norway
关键词
metastasis; prostate-specific antigen; cytokeratin; immunocytochemistry; disease progression;
D O I
10.1002/pros.20826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. The purpose of this study was to explore the prevalence of disseminated tumor cells (DTCs) in bone marrow (BM) of clinically progression-free prostate cancer (PC) patients at least 2 years after curatively intended radiotherapy (RT) with or without adjuvant hormone treatment. METHODS. All patients were T1-3N0M0 with intermediate or high risk of progression. Median time from RT to BM sampling was 5 years (2-8). A standardized immunocytochemical method applying the anticytokeratin antibodies AE1/AE3 was used for DTCs detection in 130 patients. Morphological characterization of immunostained cells was performed to exclude false positive cells. The post-treatment BM was explored in relation to pre-treatment risk factors, treatment strategy and serum levels of Testosterone and PSA at the time of BM sampling. Longitudinal changes in BM status were studied in a sub-group of 109 patients who also had donated BM prior to treatment. RESULTS. Post-treatment BM-aspirates were positive for DTCs in 17% of cases without correlation to any of the tested variables. Out of 14 patients who had DTCs in BM prior to treatment, all but one had become post-treatment negative. Out of 95 patients with pretreatment negative BM status, 18 (19%) had become post-treatment positive. CONCLUSIONS. DTCs in BM were found in 17% of clinically progression-free PC patients following RT. The detection of these cells may provide PSA-independent prognostic information remaining to be explored by prolonged follow-up. Prostate 68: 1607-1614, 2008. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:1607 / 1614
页数:8
相关论文
共 50 条
  • [21] Radical prostatectomy for high-risk prostate cancer
    Yossepowitch, Ofer
    Eastham, James A.
    [J]. WORLD JOURNAL OF UROLOGY, 2008, 26 (03) : 219 - 224
  • [22] Radical Prostatectomy for High-risk Prostate Cancer
    Karnes, R. Jeffrey
    Hatano, Tadashi
    Blute, Michael L.
    Myers, Robert P.
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 3 - 9
  • [23] Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy
    da Silva Franca, Carlos Antonio
    Vieira, Sergio L.
    Carvalho, Antonio Carlos P.
    Bernabe, Antonio Jose S.
    Penna, Antonio Belmiro Rodrigues C.
    [J]. BRACHYTHERAPY, 2010, 9 (04) : 307 - 312
  • [24] Extended vs standard pelvic lymphadenectomy during laparoscopic radical prostatectomy for intermediate- and high-risk prostate cancer
    Eden, Christopher G.
    Arora, Avanish
    Rouse, Paul
    [J]. BJU INTERNATIONAL, 2010, 106 (04) : 537 - 542
  • [25] Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
    Volmer, Lea
    Koch, Andre
    Matovina, Sabine
    Dannehl, Dominik
    Weiss, Martin
    Welker, Ganna
    Hahn, Markus
    Engler, Tobias
    Wallwiener, Markus
    Walter, Christina Barbara
    Oberlechner, Ernst
    Brucker, Sara Yvonne
    Pantel, Klaus
    Hartkopf, Andreas
    [J]. CANCERS, 2022, 14 (03)
  • [26] IMMUNOCYTOCHEMICAL DETECTION AND PHENOTYPIC CHARACTERIZATION OF MICROMETASTATIC TUMOR-CELLS IN BONE-MARROW OF PATIENTS WITH PROSTATE-CANCER
    OBERNEDER, R
    RIESENBERG, R
    KRIEGMAIR, M
    BITZER, U
    KLAMMERT, R
    SCHNEEDE, P
    HOFSTETTER, A
    RIETHMULLER, G
    PANTEL, K
    [J]. UROLOGICAL RESEARCH, 1994, 22 (01): : 3 - 8
  • [27] Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma
    Buchner, A
    Riesenberg, R
    Kotter, I
    Hofstetter, A
    Stief, C
    Oberneder, R
    [J]. CANCER, 2006, 106 (07) : 1514 - 1520
  • [28] A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow
    Walter, Vincent P.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Walter, Christina
    Grischke, Eva-Maria
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Hartkopf, Andreas D.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (02) : 305 - 309
  • [29] immunocytochemical detection of disseminated epithelial tumor cells in bone marrow of patients with pancreatic carcinoma
    Thorban, S
    Roder, JD
    Pantel, K
    Siewert, JR
    [J]. ZENTRALBLATT FUR CHIRURGIE, 1996, 121 (06): : 487 - 489
  • [30] Is Clinical Stage T2c Prostate Cancer an Intermediate- or High-Risk Disease?
    Klaassen, Zachary
    Singh, Abhay A.
    Howard, Lauren E.
    Feng, Zhaoyong
    Trock, Bruce
    Terris, Martha K.
    Aronson, William J.
    Cooperberg, Matthew R.
    Amling, Christopher L.
    Kane, Christopher J.
    Partin, Alan
    Han, Misop
    Freedland, Stephen J.
    [J]. CANCER, 2015, 121 (09) : 1414 - 1421